Recent study also found that BCL6 has been implicated in the development of type B acute lymphocyte leukaemia, chronic myeloid leukaemia, breast cancer and non-small-cell lung carcinoma, suggesting that it might be a potential drug target. Here, BCL6 is linked to non-small cell lung carcinoma.